Abstract: The invention relates to novel N-hydroxy-substituted 1,2,3,6-tetrahydropyridine and piperidine derivatives of the formula ##STR1## wherein A, B, D, E, G, I and R are as defined in the specification, m is 0, 1 or 2, with the proviso that:m is 0 or 2, or both G and I are hydrogen, when A is benzyl or halogen-monosubstituted benzyl group; andm is 1, when A is 2-picolyl, as well as their pharmaceutically acceptable acid addition salts. The compounds of formula (I) are useful for enhancing the tolerance of mammals (including man) against hypoxic and/or ischaemic states as well as for treating the degenerative and functional disturbances arising from hypoxic and/or ischaemic results.

Abstract: The invention relates to novel 17.beta.-substituted 4-azaandrostane derivatives of general formula (I), ##STR1## wherein R means hydrogen or a C.sub.1-3 alkyl group;R.sup.1 and R.sup.2 are the same or different and stand for hydrogen or a C.sub.1-4 alkyl group with the proviso that both can mean hydrogen only in the case when n is higher than 5; orR.sup.1 and R.sup.2 together means an .alpha.,.omega.-alkylene group containing 5 to 7 carbon atoms, the terminal carbon atoms of said alkylene group being bound to the same ring carbon atom;n is 4, 5, 6 or 7; and--- bond line represents a single or double bond.Furthermore, the invention relates to pharmaceutical composition containing these compounds as well as a process for the preparation of the compounds of general formula (I).The compounds of general formula (I) exert a 5.alpha.

Abstract: The invention relates to carbazolone derivatives of the formula ##STR1## wherein A stands for a group of formula--CH.sub.2 --R (V),wherein R means a hydroxyl or 2-methyl-1H-imidazol-1-yl group;B represents a group of formula ##STR2## wherein R.sub.1 means hydrogen or a methyl or ethyl group; or A and B together form a group of formula ##STR3## wherein R.sub.2 means a methyl or ethyl group; or A and B together form a group of formula ##STR4## The above compounds are useful intermediates in the synthesis of ondansetron of formula ##STR5## chemically 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carba zol-4-one.The invention further relates to a novel process for the preparation of compounds of the formula (I) , wherein A and B are the same as in formula (I) but B may be also hydrogen. Thus, this novel process is suitable for the preparation of ondansetron itself.

Abstract: The invention relates to carbazolone derivatives of the formula ##STR1## wherein A stands for a group of formula--CH.sub.2 --R (V),wherein R means a hydroxyl or 2-methyl-1H-imidazol-1-yl group;B represents a group of formula ##STR2## wherein R.sub.1 means hydrogen or a methyl or ethyl group; or A and B together form a group of formula ##STR3## wherein R.sub.2 means a methyl or ethyl group; or A and B together form a group of formula ##STR4## The above compounds are useful intermediates in the synthesis of ondansetron of formula ##STR5## chemically 9-methyl-3-[(2-methyl)-1H-imidzol-1-yl)methyl]1,2,3,9-tetrahydro-4H-carbaz ol-4-one.The invention further relates to a novel process for the preparation of compounds of the formula (I), wherein A and B are the same as in formula (I) but B may be also hydrogen. Thus, this novel process is suitable for the preparation of ondansetron itself.

Abstract: The present invention relates to novel 1,2,3,6-tetrahydropyridine derivatives of the general formula (I) ##STR1## wherein R stands for hydrogen or an alkyl group,X stands for an unsubstituted phenyl or benzyl group or for a phenyl or benzyl group substituted with a halogen atom,Y stands for hydrogen or halogen or a trifluoro-methyl groupas well as enantiomers acid addition salts thereof.The invention further extends to pharmaceutical compositions containing said compounds as active ingredient mainly for improving cerebral blood circulation and antihypoxic activity.

Abstract: The present invention relates to novel compounds of the general formula (I) ##STR1## wherein R means hydrogen or C.sub.1-4 alkyl group; andY stands for cyano, trifluoromethyl, aryloxy or aryl(C.sub.1-4 alkyl)oxy group.The compounds according to the invention show a gastric acid secretion-inhibiting effect and therefore, they are useful for the treatment of gastric and duodenal ulcers. In addition, they exert a cytoprotective action against gastric laesions induced, e.g. by indomethacin or acid-containing alcohol.

Abstract: Novel antihyperlipoproteinemic compounds are disclosed of the formula I, ##STR1## wherein X is a halogen atom, methyl, ethyl, methoxy or ethoxy group,Y is hydroxy if X is methoxy or ethoxy, otherwise it is a hydrogen atom or a, methoxy or ethoxy group,Z is a methoxy or ethoxy group if X or Y is a methoxy group or an ethoxy group; otherwise it is hydrogen atom,The invention also covers antiartheriosclerotic, antihyperlipoproteinemic pharmaceutical compositions, suitable for inhibiting the formation of thrombuses, comprising the compounds of formula I in an effective dose, a process for preparing the same and methods for the treatment of hyperlipoproteinemia with the aid of the said compounds or compositions.